The global analgesics market size accounted for USD 46.47 billion in 2025, and is anticipated to reach around USD 79.86 billion by 2034, poised to grow at a CAGR of 6.20% between 2025 and 2034. The North America analgesics market size surpassed USD 18.38 billion in 2024 and is estimated to grow at the fastest CAGR of 6.33% during the forecast year. The market sizing and forecasts are revenue-based (USD Million/Billion), with 2024 as the base year.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. Market Dynamics
5.1.1. Market Drivers
5.1.2. Market Restraints
5.1.3. Market Opportunities
5.2. Porter’s Five Forces Analysis
5.2.1. Bargaining power of suppliers
5.2.2. Bargaining power of buyers
5.2.3. Threat of substitute
5.2.4. Threat of new entrants
5.2.5. Degree of competition
6.1.1. Company Market Share/Positioning Analysis
6.1.2. Key Strategies Adopted by Players
6.1.3. Vendor Landscape
6.1.3.1. List of Suppliers
6.1.3.2. List of Buyers
7.1. Analgesics Market, by Drug Class
7.1.1. Opioids
7.1.1.1. Market Revenue and Forecast
7.1.2. NSAIDs
7.1.2.1. Market Revenue and Forecast
7.1.3. Local Anesthetics
7.1.3.1. Market Revenue and Forecast
7.1.4. Acetaminophen
7.1.4.1. Market Revenue and Forecast
8.1. Analgesics Market, by Indication
8.1.1. Surgical Pain
8.1.1.1. Market Revenue and Forecast
8.1.2. Cancer Pain
8.1.2.1. Market Revenue and Forecast
8.1.3. Neuropathic Pain
8.1.3.1. Market Revenue and Forecast
8.1.4. Others
8.1.4.1. Market Revenue and Forecast
9.1. Analgesics Market, by Type
9.1.1. Prescription
9.1.1.1. Market Revenue and Forecast
9.1.2. OTC
9.1.2.1. Market Revenue and Forecast
10.1. Analgesics Market, by Pain Type
10.1.1. Musculoskeletal Pain
10.1.1.1. Market Revenue and Forecast
10.1.2. Surgical and Trauma Pain
10.1.2.1. Market Revenue and Forecast
10.1.3. Cancer Pain
10.1.3.1. Market Revenue and Forecast
10.1.4. Neuropathic Pain
10.1.4.1. Market Revenue and Forecast
10.1.5. Migraine
10.1.5.1. Market Revenue and Forecast
10.1.6. Obstetrical Pain
10.1.6.1. Market Revenue and Forecast
10.1.7. Fibromyalgia
10.1.7.1. Market Revenue and Forecast
10.1.8. Pain due to Burns
10.1.8.1. Market Revenue and Forecast
10.1.9. Dental/Facial Pain
10.1.9.1. Market Revenue and Forecast
10.1.10. Paediatric Pain
10.1.10.1. Market Revenue and Forecast
10.1.11. Others
10.1.11.1. Market Revenue and Forecast
11.1. Analgesics Market, by Application
11.1.1. Internal Analgesics
11.1.1.1. Market Revenue and Forecast
11.1.2. External Analgesics
11.1.2.1. Market Revenue and Forecast
12.1. Analgesics Market, by Route of Administration
12.1.1. Oral
12.1.1.1. Market Revenue and Forecast
12.1.2. Oral
12.1.2.1. Market Revenue and Forecast
12.1.3. Transdermal
12.1.3.1. Market Revenue and Forecast
12.1.4. Others
12.1.4.1. Market Revenue and Forecast
13.1. Analgesics Market, by Distribution Channel
13.1.1. Hospital pharmacies
13.1.1.1. Market Revenue and Forecast
13.1.2. Retail pharmacies
13.1.2.1. Market Revenue and Forecast
13.1.3. Drug Stores
13.1.3.1. Market Revenue and Forecast
13.1.4. Online pharmacies
13.1.4.1. Market Revenue and Forecast
14.1. North America
14.1.1. Market Revenue and Forecast, by Drug Class
14.1.2. Market Revenue and Forecast, by Indication
14.1.3. Market Revenue and Forecast, by Type
14.1.4. Market Revenue and Forecast, by Pain Type
14.1.5. Market Revenue and Forecast, by Application
14.1.6. Market Revenue and Forecast, by Distribution Channel
14.1.7. Market Revenue and Forecast, by Route of Administration
14.1.8. U.S.
14.1.8.1. Market Revenue and Forecast, by Drug Class
14.1.8.2. Market Revenue and Forecast, by Indication
14.1.8.3. Market Revenue and Forecast, by Type
14.1.8.4. Market Revenue and Forecast, by Pain Type
14.1.8.5. Market Revenue and Forecast, by Application
14.1.8.6. Market Revenue and Forecast, by Distribution Channel
14.1.8.7. Market Revenue and Forecast, by Route of Administration
14.1.9. Rest of North America
14.1.9.1. Market Revenue and Forecast, by Drug Class
14.1.9.2. Market Revenue and Forecast, by Indication
14.1.9.3. Market Revenue and Forecast, by Type
14.1.9.4. Market Revenue and Forecast, by Pain Type
14.1.9.5. Market Revenue and Forecast, by Application
14.1.9.6. Market Revenue and Forecast, by Distribution Channel
14.1.9.7. Market Revenue and Forecast, by Route of Administration
14.2. Europe
14.2.1. Market Revenue and Forecast, by Drug Class
14.2.2. Market Revenue and Forecast, by Indication
14.2.3. Market Revenue and Forecast, by Type
14.2.4. Market Revenue and Forecast, by Pain Type
14.2.5. Market Revenue and Forecast, by Application
14.2.6. Market Revenue and Forecast, by Distribution Channel
14.2.7. Market Revenue and Forecast, by Route of Administration
14.2.8. UK
14.2.8.1. Market Revenue and Forecast, by Drug Class
14.2.8.2. Market Revenue and Forecast, by Indication
14.2.8.3. Market Revenue and Forecast, by Type
14.2.8.4. Market Revenue and Forecast, by Pain Type
14.2.8.5. Market Revenue and Forecast, by Application
14.2.8.6. Market Revenue and Forecast, by Distribution Channel
14.2.8.7. Market Revenue and Forecast, by Route of Administration
14.2.9. Germany
14.2.9.1. Market Revenue and Forecast, by Drug Class
14.2.9.2. Market Revenue and Forecast, by Indication
14.2.9.3. Market Revenue and Forecast, by Type
14.2.9.4. Market Revenue and Forecast, by Pain Type
14.2.9.5. Market Revenue and Forecast, by Application
14.2.9.6. Market Revenue and Forecast, by Distribution Channel
14.2.9.7. Market Revenue and Forecast, by Route of Administration
14.2.10. France
14.2.10.1. Market Revenue and Forecast, by Drug Class
14.2.10.2. Market Revenue and Forecast, by Indication
14.2.10.3. Market Revenue and Forecast, by Type
14.2.10.4. Market Revenue and Forecast, by Pain Type
14.2.10.5. Market Revenue and Forecast, by Application
14.2.10.6. Market Revenue and Forecast, by Distribution Channel
14.2.10.7. Market Revenue and Forecast, by Route of Administration
14.2.11. Rest of Europe
14.2.11.1. Market Revenue and Forecast, by Drug Class
14.2.11.2. Market Revenue and Forecast, by Indication
14.2.11.3. Market Revenue and Forecast, by Type
14.2.11.4. Market Revenue and Forecast, by Pain Type
14.2.11.5. Market Revenue and Forecast, by Application
14.2.11.6. Market Revenue and Forecast, by Distribution Channel
14.2.11.7. Market Revenue and Forecast, by Route of Administration
14.3. APAC
14.3.1. Market Revenue and Forecast, by Drug Class
14.3.2. Market Revenue and Forecast, by Indication
14.3.3. Market Revenue and Forecast, by Type
14.3.4. Market Revenue and Forecast, by Pain Type
14.3.5. Market Revenue and Forecast, by Application
14.3.6. Market Revenue and Forecast, by Distribution Channel
14.3.7. Market Revenue and Forecast, by Route of Administration
14.3.8. India
14.3.8.1. Market Revenue and Forecast, by Drug Class
14.3.8.2. Market Revenue and Forecast, by Indication
14.3.8.3. Market Revenue and Forecast, by Type
14.3.8.4. Market Revenue and Forecast, by Pain Type
14.3.8.5. Market Revenue and Forecast, by Application
14.3.8.6. Market Revenue and Forecast, by Distribution Channel
14.3.8.7. Market Revenue and Forecast, by Route of Administration
14.3.9. China
14.3.9.1. Market Revenue and Forecast, by Drug Class
14.3.9.2. Market Revenue and Forecast, by Indication
14.3.9.3. Market Revenue and Forecast, by Type
14.3.9.4. Market Revenue and Forecast, by Pain Type
14.3.9.5. Market Revenue and Forecast, by Application
14.3.9.6. Market Revenue and Forecast, by Distribution Channel
14.3.9.7. Market Revenue and Forecast, by Route of Administration
14.3.10. Japan
14.3.10.1. Market Revenue and Forecast, by Drug Class
14.3.10.2. Market Revenue and Forecast, by Indication
14.3.10.3. Market Revenue and Forecast, by Type
14.3.10.4. Market Revenue and Forecast, by Pain Type
14.3.10.5. Market Revenue and Forecast, by Application
14.3.10.6. Market Revenue and Forecast, by Distribution Channel
14.3.10.7. Market Revenue and Forecast, by Route of Administration
14.3.11. Rest of APAC
14.3.11.1. Market Revenue and Forecast, by Drug Class
14.3.11.2. Market Revenue and Forecast, by Indication
14.3.11.3. Market Revenue and Forecast, by Type
14.3.11.4. Market Revenue and Forecast, by Pain Type
14.3.11.5. Market Revenue and Forecast, by Application
14.3.11.6. Market Revenue and Forecast, by Distribution Channel
14.3.11.7. Market Revenue and Forecast, by Route of Administration
14.4. MEA
14.4.1. Market Revenue and Forecast, by Drug Class
14.4.2. Market Revenue and Forecast, by Indication
14.4.3. Market Revenue and Forecast, by Type
14.4.4. Market Revenue and Forecast, by Pain Type
14.4.5. Market Revenue and Forecast, by Application
14.4.6. Market Revenue and Forecast, by Distribution Channel
14.4.7. Market Revenue and Forecast, by Route of Administration
14.4.8. GCC
14.4.8.1. Market Revenue and Forecast, by Drug Class
14.4.8.2. Market Revenue and Forecast, by Indication
14.4.8.3. Market Revenue and Forecast, by Type
14.4.8.4. Market Revenue and Forecast, by Pain Type
14.4.8.5. Market Revenue and Forecast, by Application
14.4.8.6. Market Revenue and Forecast, by Distribution Channel
14.4.8.7. Market Revenue and Forecast, by Route of Administration
14.4.9. North Africa
14.4.9.1. Market Revenue and Forecast, by Drug Class
14.4.9.2. Market Revenue and Forecast, by Indication
14.4.9.3. Market Revenue and Forecast, by Type
14.4.9.4. Market Revenue and Forecast, by Pain Type
14.4.9.5. Market Revenue and Forecast, by Application
14.4.9.6. Market Revenue and Forecast, by Distribution Channel
14.4.9.7. Market Revenue and Forecast, by Route of Administration
14.4.10. South Africa
14.4.10.1. Market Revenue and Forecast, by Drug Class
14.4.10.2. Market Revenue and Forecast, by Indication
14.4.10.3. Market Revenue and Forecast, by Type
14.4.10.4. Market Revenue and Forecast, by Pain Type
14.4.10.5. Market Revenue and Forecast, by Application
14.4.10.6. Market Revenue and Forecast, by Distribution Channel
14.4.10.7. Market Revenue and Forecast, by Route of Administration
14.4.11. Rest of MEA
14.4.11.1. Market Revenue and Forecast, by Drug Class
14.4.11.2. Market Revenue and Forecast, by Indication
14.4.11.3. Market Revenue and Forecast, by Type
14.4.11.4. Market Revenue and Forecast, by Pain Type
14.4.11.5. Market Revenue and Forecast, by Application
14.4.11.6. Market Revenue and Forecast, by Distribution Channel
14.4.11.7. Market Revenue and Forecast, by Route of Administration
14.5. Latin America
14.5.1. Market Revenue and Forecast, by Drug Class
14.5.2. Market Revenue and Forecast, by Indication
14.5.3. Market Revenue and Forecast, by Type
14.5.4. Market Revenue and Forecast, by Pain Type
14.5.5. Market Revenue and Forecast, by Application
14.5.6. Market Revenue and Forecast, by Distribution Channel
14.5.7. Market Revenue and Forecast, by Route of Administration
14.5.8. Brazil
14.5.8.1. Market Revenue and Forecast, by Drug Class
14.5.8.2. Market Revenue and Forecast, by Indication
14.5.8.3. Market Revenue and Forecast, by Type
14.5.8.4. Market Revenue and Forecast, by Pain Type
14.5.8.5. Market Revenue and Forecast, by Application
14.5.8.6. Market Revenue and Forecast, by Distribution Channel
14.5.8.7. Market Revenue and Forecast, by Route of Administration
14.5.9. Rest of LATAM
14.5.9.1. Market Revenue and Forecast, by Drug Class
14.5.9.2. Market Revenue and Forecast, by Indication
14.5.9.3. Market Revenue and Forecast, by Type
14.5.9.4. Market Revenue and Forecast, by Pain Type
14.5.9.5. Market Revenue and Forecast, by Application
14.5.9.6. Market Revenue and Forecast, by Distribution Channel
14.5.9.7. Market Revenue and Forecast, by Route of Administration
15.1. Abbott
15.1.1. Company Overview
15.1.2. Product Offerings
15.1.3. Financial Performance
15.1.4. Recent Initiatives
15.2. Pfizer Inc.
15.2.1. Company Overview
15.2.2. Product Offerings
15.2.3. Financial Performance
15.2.4. Recent Initiatives
15.3. Eli Lilly & Company
15.3.1. Company Overview
15.3.2. Product Offerings
15.3.3. Financial Performance
15.3.4. Recent Initiatives
15.4. Endo International plc
15.4.1. Company Overview
15.4.2. Product Offerings
15.4.3. Financial Performance
15.4.4. Recent Initiatives
15.5. F. Hoffmann-La Roche AG
15.5.1. Company Overview
15.5.2. Product Offerings
15.5.3. Financial Performance
15.5.4. Recent Initiatives
15.6. Bausch Health Companies Inc.
15.6.1. Company Overview
15.6.2. Product Offerings
15.6.3. Financial Performance
15.6.4. Recent Initiatives
15.7. Merck & Co. Inc.
15.7.1. Company Overview
15.7.2. Product Offerings
15.7.3. Financial Performance
15.7.4. Recent Initiatives
15.8. AbbVie Inc.
15.8.1. Company Overview
15.8.2. Product Offerings
15.8.3. Financial Performance
15.8.4. Recent Initiatives
15.9. Novartis AG
15.9.1. Company Overview
15.9.2. Product Offerings
15.9.3. Financial Performance
15.9.4. Recent Initiatives
15.10. Johnson & Johnson Private Limited
15.10.1. Company Overview
15.10.2. Product Offerings
15.10.3. Financial Performance
15.10.4. Recent Initiatives
16.1. Primary Research
16.2. Secondary Research
16.3. Assumptions
17.1. About Us
17.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
Plan your call and get expert insights!
Schedule a Meeting
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample